Nurix Roe vs Price To Sales Ratio Analysis

NRIX Stock

USD 16.33 0.53 3.14%

Nurix Therapeutics financial indicator trend analysis is infinitely more than just investigating Nurix Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nurix Therapeutics is a good investment. Please check the relationship between Nurix Therapeutics Roe and its Price To Sales Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nurix Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

Roe vs Price To Sales Ratio

Roe vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nurix Therapeutics Roe account and Price To Sales Ratio. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Nurix Therapeutics' Roe and Price To Sales Ratio is -0.02. Overlapping area represents the amount of variation of Roe that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Nurix Therapeutics, assuming nothing else is changed. The correlation between historical values of Nurix Therapeutics' Roe and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Roe of Nurix Therapeutics are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Roe i.e., Nurix Therapeutics' Roe and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

-0.02

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Roe

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Nurix Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Nurix Therapeutics sales, a figure that is much harder to manipulate than other Nurix Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.

Most indicators from Nurix Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nurix Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nurix Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.At this time, Nurix Therapeutics' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value is likely to rise to about 475.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 26.3 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	3.5M	11.1M	12.8M	13.4M
Net Interest Income	3.5M	11.1M	12.8M	13.4M

Interest Income Net Interest Income

Nurix Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.79	0.85	0.99	0.88	0.99	0.75	0.76	-0.57	-0.8	0.94	0.87	0.96	0.83	0.4	0.99	0.98	0.75	0.97	0.47	0.92	0.98	0.81	0.81	0.99	0.67
Other Current Liab	0.79		0.89	0.73	0.61	0.79	0.98	0.78	0.01	-0.98	0.88	0.48	0.67	0.91	-0.08	0.82	0.83	0.89	0.87	0.54	0.96	0.83	1.0	0.87	0.73	0.95
Total Current Liabilities	0.85	0.89		0.79	0.59	0.89	0.88	0.95	-0.12	-0.91	0.95	0.53	0.72	0.92	0.06	0.89	0.92	0.85	0.94	0.49	0.9	0.86	0.9	0.92	0.79	0.84
Total Stockholder Equity	0.99	0.73	0.79		0.88	0.98	0.68	0.71	-0.64	-0.73	0.89	0.89	0.97	0.79	0.45	0.97	0.96	0.68	0.94	0.38	0.89	0.98	0.76	0.73	1.0	0.59
Other Liab	0.88	0.61	0.59	0.88		0.85	0.59	0.42	-0.69	-0.62	0.79	0.91	0.88	0.6	0.53	0.86	0.84	0.67	0.8	0.66	0.77	0.83	0.62	0.71	0.88	0.53
Net Tangible Assets	0.99	0.79	0.89	0.98	0.85		0.76	0.8	-0.53	-0.82	0.95	0.84	0.93	0.85	0.39	1.0	0.99	0.77	0.99	0.49	0.92	0.97	0.82	0.84	0.98	0.69
Property Plant And Equipment Net	0.75	0.98	0.88	0.68	0.59	0.76		0.78	0.04	-0.97	0.86	0.47	0.62	0.84	-0.05	0.79	0.8	0.85	0.83	0.61	0.94	0.77	0.97	0.89	0.68	0.99
Current Deferred Revenue	0.76	0.78	0.95	0.71	0.42	0.8	0.78		-0.09	-0.79	0.85	0.47	0.64	0.79	0.08	0.79	0.81	0.65	0.84	0.32	0.79	0.75	0.79	0.81	0.71	0.76
Net Debt	-0.57	0.01	-0.12	-0.64	-0.69	-0.53	0.04	-0.09		0.02	-0.28	-0.86	-0.62	-0.09	-0.89	-0.52	-0.47	-0.01	-0.4	-0.08	-0.28	-0.47	-0.01	-0.12	-0.64	0.11
Retained Earnings	-0.8	-0.98	-0.91	-0.73	-0.62	-0.82	-0.97	-0.79	0.02		-0.89	-0.5	-0.65	-0.91	0.0	-0.84	-0.86	-0.9	-0.89	-0.56	-0.95	-0.82	-0.97	-0.89	-0.73	-0.94
Accounts Payable	0.94	0.88	0.95	0.89	0.79	0.95	0.86	0.85	-0.28	-0.89		0.68	0.87	0.92	0.13	0.95	0.96	0.89	0.97	0.62	0.93	0.94	0.9	0.94	0.89	0.8
Cash	0.87	0.48	0.53	0.89	0.91	0.84	0.47	0.47	-0.86	-0.5	0.68		0.86	0.47	0.77	0.84	0.8	0.43	0.76	0.4	0.71	0.78	0.5	0.55	0.89	0.42
Non Current Assets Total	0.96	0.67	0.72	0.97	0.88	0.93	0.62	0.64	-0.62	-0.65	0.87	0.86		0.73	0.37	0.91	0.89	0.64	0.88	0.39	0.82	0.95	0.72	0.68	0.97	0.53
Non Currrent Assets Other	0.83	0.91	0.92	0.79	0.6	0.85	0.84	0.79	-0.09	-0.91	0.92	0.47	0.73		-0.09	0.86	0.89	0.91	0.92	0.41	0.89	0.9	0.93	0.84	0.79	0.77
Other Assets	0.4	-0.08	0.06	0.45	0.53	0.39	-0.05	0.08	-0.89	0.0	0.13	0.77	0.37	-0.09		0.39	0.34	-0.13	0.27	0.09	0.19	0.26	-0.09	0.08	0.45	-0.06
Cash And Short Term Investments	0.99	0.82	0.89	0.97	0.86	1.0	0.79	0.79	-0.52	-0.84	0.95	0.84	0.91	0.86	0.39		1.0	0.79	0.99	0.5	0.94	0.97	0.84	0.85	0.97	0.72
Common Stock Total Equity	0.98	0.83	0.92	0.96	0.84	0.99	0.8	0.81	-0.47	-0.86	0.96	0.8	0.89	0.89	0.34	1.0		0.82	1.0	0.52	0.94	0.97	0.85	0.88	0.96	0.73
Common Stock Shares Outstanding	0.75	0.89	0.85	0.68	0.67	0.77	0.85	0.65	-0.01	-0.9	0.89	0.43	0.64	0.91	-0.13	0.79	0.82		0.84	0.73	0.85	0.8	0.88	0.92	0.68	0.81
Short Term Investments	0.97	0.87	0.94	0.94	0.8	0.99	0.83	0.84	-0.4	-0.89	0.97	0.76	0.88	0.92	0.27	0.99	1.0	0.84		0.5	0.95	0.97	0.89	0.88	0.94	0.76
Non Current Liabilities Total	0.47	0.54	0.49	0.38	0.66	0.49	0.61	0.32	-0.08	-0.56	0.62	0.4	0.39	0.41	0.09	0.5	0.52	0.73	0.5		0.54	0.42	0.51	0.79	0.38	0.64
Capital Surpluse	0.92	0.96	0.9	0.89	0.77	0.92	0.94	0.79	-0.28	-0.95	0.93	0.71	0.82	0.89	0.19	0.94	0.94	0.85	0.95	0.54		0.93	0.96	0.87	0.89	0.89
Other Current Assets	0.98	0.83	0.86	0.98	0.83	0.97	0.77	0.75	-0.47	-0.82	0.94	0.78	0.95	0.9	0.26	0.97	0.97	0.8	0.97	0.42	0.93		0.86	0.79	0.98	0.68
Other Stockholder Equity	0.81	1.0	0.9	0.76	0.62	0.82	0.97	0.79	-0.01	-0.97	0.9	0.5	0.72	0.93	-0.09	0.84	0.85	0.88	0.89	0.51	0.96	0.86		0.86	0.76	0.93
Total Liab	0.81	0.87	0.92	0.73	0.71	0.84	0.89	0.81	-0.12	-0.89	0.94	0.55	0.68	0.84	0.08	0.85	0.88	0.92	0.88	0.79	0.87	0.79	0.86		0.73	0.88
Net Invested Capital	0.99	0.73	0.79	1.0	0.88	0.98	0.68	0.71	-0.64	-0.73	0.89	0.89	0.97	0.79	0.45	0.97	0.96	0.68	0.94	0.38	0.89	0.98	0.76	0.73		0.59
Property Plant And Equipment Gross	0.67	0.95	0.84	0.59	0.53	0.69	0.99	0.76	0.11	-0.94	0.8	0.42	0.53	0.77	-0.06	0.72	0.73	0.81	0.76	0.64	0.89	0.68	0.93	0.88	0.59

Click cells to compare fundamentals

Nurix Therapeutics Account Relationship Matchups

Nurix Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	396.3M	476.8M	416.8M	364.5M	419.2M	319.7M
Other Current Liab	700K	14.5M	22.4M	25.0M	28.7M	30.2M
Total Current Liabilities	44.5M	66.3M	70.7M	87.0M	100.0M	58.2M
Total Stockholder Equity	290.3M	342.3M	303.7M	200.5M	230.6M	191.1M
Other Liab	37.4M	61.5M	59.0M	36.0M	41.4M	42.9M
Net Tangible Assets	(57.7M)	290.3M	342.3M	303.7M	349.3M	185.2M
Property Plant And Equipment Net	6.7M	25.3M	29.5M	48.0M	55.1M	57.9M
Current Deferred Revenue	32.8M	41.2M	37.6M	48.1M	55.3M	36.3M
Net Debt	(119.4M)	(67.5M)	(52.5M)	(24.0M)	(27.6M)	(29.0M)
Retained Earnings	(103.7M)	(220.9M)	(401.3M)	(545.2M)	(490.7M)	(466.1M)
Accounts Payable	3.4M	6.7M	5.1M	6.4M	7.4M	4.5M
Cash	119.4M	80.5M	64.5M	54.6M	62.8M	69.6M
Non Current Assets Total	97.9M	165.7M	98.3M	69.0M	79.4M	80.7M
Non Currrent Assets Other	347K	3.1M	4.9M	3.8M	4.4M	2.4M
Other Assets	317K	91.2M	3.1M	4.9M	5.7M	5.4M
Cash And Short Term Investments	281.1M	295.7M	309.1M	287.9M	331.1M	229.3M
Common Stock Total Equity	4K	39K	45K	47K	54.1K	30.4K
Common Stock Shares Outstanding	15.7M	42.9M	48.6M	54.3M	62.5M	39.7M
Short Term Investments	161.8M	215.2M	244.7M	233.3M	268.3M	159.7M
Liabilities And Stockholders Equity	396.3M	476.8M	416.8M	364.5M	419.2M	319.7M
Non Current Liabilities Total	61.5M	68.2M	42.4M	77.1M	88.7M	70.5M
Capital Surpluse	2.7M	393.8M	563.8M	709.2M	815.6M	856.4M
Other Current Assets	5.9M	9.2M	9.3M	6.8M	7.8M	6.3M
Other Stockholder Equity	(2.5M)	563.8M	709.2M	746.3M	858.2M	901.2M
Total Liab	106.1M	134.5M	113.1M	164.0M	188.7M	128.6M
Net Invested Capital	290.3M	342.3M	303.7M	200.5M	230.6M	191.1M
Long Term Investments	90.9M	137.2M	63.9M	7.4M	8.5M	8.1M
Property Plant And Equipment Gross	6.7M	25.3M	29.5M	74.2M	85.3M	89.6M
Total Current Assets	298.4M	311.1M	318.4M	295.5M	339.8M	239.0M
Accumulated Other Comprehensive Income	87K	(608K)	(4.3M)	(655K)	(589.5K)	(619.0K)
Capital Stock	39K	45K	47K	49K	56.4K	34.3K
Non Current Liabilities Other	1.7M	850K	68.2M	42.4M	48.8M	25.2M
Net Working Capital	253.9M	244.9M	247.8M	208.5M	239.8M	180.8M
Short Term Debt	7.6M	3.8M	5.5M	7.5M	8.6M	5.9M
Common Stock	39K	45K	47K	49K	56.4K	34.3K
Property Plant Equipment	3.9M	6.7M	25.3M	17.2M	19.7M	12.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

VTSNX	Vanguard Total International
VBTIX	Vanguard Total Bond
VMCIX	Vanguard Mid Cap Index

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nurix Roe vs Price To Sales Ratio Analysis

Roe vs Price To Sales Ratio

Roe vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Roe

Price To Sales Ratio

Nurix Therapeutics fundamental ratios Correlations

Nurix Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nurix Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Nurix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Stockholder Equity	+ 1.0	Other Current Liab
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Net Tangible Assets
Common Stock Total Equity	+ 1.0	Cash And Short Term Investments
Short Term Investments	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets

Retained Earnings	- 0.98	Other Current Liab
Other Stockholder Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Property Plant And Equipment Net
Capital Surpluse	- 0.95	Retained Earnings
Property Plant And Equipment Gross	- 0.94	Retained Earnings
Non Currrent Assets Other	- 0.91	Retained Earnings